AKT1 E17K inhibitor ALTA2618

An orally bioavailable covalent inhibitor of the serine/threonine protein kinase AKT (protein kinase B; v-akt murine thymoma viral oncogene homolog 1) isoform 1 mutation AKT1 E17K, with potential antineoplastic activity. Upon oral administration, AKT1 E17K inhibitor ALTA2618 targets, allosterically binds to and inhibits AKT1 E17K. This may inhibit growth of and induce apoptosis in AKT1 E17K-driven cancers. AKT1 E17K, overexpressed in a variety of cancer cell types, drives cancer cell proliferation. By specifically targeting the E17K mutant variant, ALTA2618 may avoid the toxicities associated with wild-type (WT) AKT inhibition.